Author:
Maretti-Mira Ana C.,Salomon Matthew P.,Hsu Angela M.,Matsuba Chikako,Golden-Mason Lucy
Abstract
IntroductionDespite advancements in hepatitis C virus (HCV) infection treatment, HCV still represents a significant public health burden. Besides progressive hepatic damage, viral persistence has lasting effects on innate and adaptive immune responses. Lack of a complete understanding of the factors driving an effective HCV response contributes to the failure to develop a vaccine for prevention. This study advances the existing knowledge on HCV-specific CD8+ T cells and describes the impact of current or past HCV infection on CD8+ T cells specific for other viruses.MethodsWe used barcoded-dextramers to identify and sort CD8+ T cells specific for HCV, cytomegalovirus, and influenza, and characterized them using single-cell RNA sequencing technology. Our cohort included chronic (cHCV), spontaneously resolved (rHCV), and subjects undergoing direct-acting antiviral (DAA) therapy.ResultsWe show that HCV-specific CD8+ T cells have cytotoxic features in patients with cHCV, which is progressively reduced with DAA therapy and persists 12 weeks after treatment completion. We also observe a shift in the CD8+ T cell phenotype on DAA treatment, with decreased effector memory and exhausted cell signatures. In rHCV, we also detected a smaller proportion of effector memory cells compared to cHCV. The proportion of CD8+ exhausted T cells in cHCV and rHCV subjects was comparable. Moreover, we also observed that non-HCV virus-specific CD8+ T cells exhibit robust cytotoxic traits during cHCV infection.DiscussionAltogether, our findings suggest that cHCV infection promotes cytotoxicity in CD8+ T cells regardless of virus specificity. The immunological changes caused by cHCV infection in CD8+ T cells may contribute to worsening the ongoing hepatic damage caused by HCV infection or exacerbate the immune response to possible co-infections. Our data provide a resource to groups exploring the underlying mechanisms of HCV-specific T cell spontaneous and treatment-induced resolution to inform the development of effective vaccines against HCV infection.
Funder
National Institute of Diabetes and Digestive and Kidney Diseases
Reference54 articles.
1. Prevalence of hepatitis c virus infection in US states and the district of Columbia, 2013 to 2016;Rosenberg;JAMA Netw Open,2018
2. Hepatitis c vaccines, antibodies, and T cells;Shoukry;Front Immunol,2018
3. New direct-acting antivirals for the treatment of patients with hepatitis c virus infection: a systematic review of randomized controlled trials;Pecoraro;J Clin Exp Hepatol,2019
4. Hepatitis c: review of the epidemiology, clinical care, and continued challenges in the direct acting antiviral era;Millman;Curr Epidemiol Rep,2017
5. Challenges and promise of a hepatitis c virus vaccine;Cox;Cold Spring Harb Perspect Med,2020
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献